Truist Securities Maintains Buy on HCA Healthcare, Raises Price Target to $430
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained its Buy rating on HCA Healthcare and raised the price target from $390 to $430, indicating confidence in the company's future performance.
August 19, 2024 | 2:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reaffirmed its Buy rating for HCA Healthcare and increased the price target from $390 to $430, suggesting a positive outlook for the company's stock.
The increase in the price target from $390 to $430 by Truist Securities indicates a strong positive sentiment towards HCA Healthcare's future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100